RxDoctor Payments Data

Shriram Sirsikar, MD

Internal Medicine · Johnstown, PANPI 1245239391

Payments from drug & device makers

$6,211in general payments, 2019–2025

Across 383 payments — averaging $16.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$1K
  • Pfizer$949
  • AbbVie$591
  • GSK$426
  • Novo Nordisk$393
  • Johnson & Johnson$309
  • plus $2K from 39 others

What the payments were for

  • Food & beverage$6,211100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,211 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$271,840
Medicare patients
399
Services billed
3,320

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban373$302,913
JardianceEmpagliflozin112$102,096
TradjentaLinagliptin93$69,556
XareltoRivaroxaban76$58,594
OzempicSemaglutide45$43,571
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$41,088
ProliaDenosumab15$25,506
JanuviaSitagliptin Phosphate15$20,136
EntrestoSacubitril/Valsartan27$19,780
MyrbetriqMirabegron22$18,015
Breo ElliptaFluticasone/Vilanterol35$17,710
MounjaroTirzepatide16$16,684
LinzessLinaclotide18$15,169
Potassium Chloride376$12,112
BrilintaTicagrelor17$11,535

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$949$302,913373 claims
Boehringer IngelheimJardiance, Tradjenta$120$171,652205 claims
GSKTrelegy Ellipta, Breo Ellipta$426$58,79893 claims
Johnson & JohnsonXarelto$309$58,59476 claims
Novo NordiskOzempic$393$43,57145 claims
AbbVieLinzess, Synthroid, Alphagan P$591$26,013157 claims
AmgenProlia$198$25,50615 claims
MerckJanuvia$123$20,13615 claims
NovartisEntresto$11$19,78027 claims
Astellas Pharma US IncMyrbetriq$24$18,01522 claims
Lilly USA, LLCMounjaro$141$16,68416 claims
AstraZenecaBrilinta$176$11,53517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Johnstown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →